The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
COVID-19 and the liver: little cause for concern
Open accessAbstract
The largest study on COVID-19 to date showed that the prevalence of elevated aminotransferases and bilirubin in people faring worst was at least double that of others. Although clinically significant liver dysfunction was not quantified, this and other studies have led some to suggest that this finding might present clinical challenges. Close inspection of the available data supports a higher prevalence of abnormal aminotransferase levels in severe COVID-19 disease, but these studies actually suggest that clinically significant liver injury is uncommon, even when data for the most severely ill patients are selected (table). Although high levels of positive end expiratory pressure can contribute to hepatic congestion by increasing right atrial pressure and impeding venous return, data suggest that many patients admitted to hospital with COVID-19 have liver blood test abnormalities without mechanical ventilation. Furthermore, the distribution of aminotransferase levels among patients with COVID-19 do not support hypoxic hepatitis being a common phenomenon, according to the published literature. Drug-induced liver injury is a possible contributing factor to the observed abnormal liver blood test abnormalities after therapeutics begin and should be considered by clinicians, but mild liver test derangement is present at baseline in many patients with COVID-19 before significant medication use. Several studies have reported elevated levels of creatinine kinase and lactate dehydrogenase or myoglobin in association with COVID-19 severity (table). It is therefore possible that aminotransferase elevations do not necessarily arise from the liver alone and that COVID-19 infection might induce a myositis similar to that observed in severe influenza infections. It has been proposed that COVID-19 causes direct liver injury via a viral hepatitis, but we believe that there are alternative explanations. First, the derangement of liver function is clearly mild. Second, when liver function tests for patients with different durations of symptoms are examined, there is no evidence that later presentation is associated with greater liver function derangement. The only post-mortem liver biopsy from a patient with COVID-19 showed only microvesicular steatosis, a common finding in sepsis. Most importantly, other respiratory viruses produce similar elevations of liver function biomarkers, which is thought to relate to hepatic damage from immune interactions involving intrahepatic cytotoxic T cells and Kupffer cells. This phenomenon waxes and wanes in parallel with respiratory viral disease and in the absence of hepatic viral replication, which might explain why worse outcomes were not seen in the 42 patients with chronic liver disease and COVID-19 who had outcome data (table). Hepatic dysfunction in severe COVID-19 is accompanied by greater activation of coagulative and fibrinolytic pathways, relatively depressed platelet counts, climbing neutrophil counts and neutrophil to lymphocyte ratios, and high ferritin levels. Although these markers are seen as non-specific markers of inflammation, we believe that they fit the paradigm of disease severity coinciding with a failure of innate immune regulation. Such unbalanced immunity favours NETosis and coagulation activation and possibly also alters systemic iron metabolism secondary to macrophage activation. Notably, this alteration of immune balance occurs with increased age, and older patients might therefore be expected to fare worse, with a greater reliance on this pathway. Clinicians cannot be complacent about the risks of COVID-19 in patients with chronic liver diseases and cirrhosis, because these patients have poor immune function and worse outcomes from acute respiratory distress syndrome than the rest of the critically ill
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study
Shi, H., Han, X., Jiang, N., Cao, Y., Alwalid, O., Gu, J., Fan, Y., & Zheng, C. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30086-4 · Cited by 3,664
Liver injury in COVID-19: management and challenges
Zhang, C., Shi, L., & Wang, F.-S. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(20)30057-1 · Cited by 1,906
Evolution of the immune system in humans from infancy to old age
Simon, A. K., Hollander, G. A., & McMichael, A. (2015) · Proceedings of the Royal Society B: Biological Sciences · doi:10.1098/rspb.2014.3085 · Cited by 1,796
Narasaraju, T., Yang, E., Samy, R. P., Ng, H. H., Poh, W. P., Liew, A.-A., Phoon, M. C., van Rooijen, N., & Chow, V. T. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.03.013 · Cited by 890
Gastrointestinal and hepatic manifestations of COVID-19: A comprehensive review
Cha, M. H., Regueiro, M., & Sandhu, D. S. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i19.2323 · Cited by 180
Systemic Viral Infections and Collateral Damage in the Liver
Adams, D. H., & Hubscher, S. G. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.051296 · Cited by 159
Liver diseases in COVID-19: Etiology, treatment and prognosis
Wu, J., Song, S., Cao, H., & Li, L.-J. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i19.2286 · Cited by 157
Cited by
Extrapulmonary manifestations of COVID-19
Gupta, A., Madhavan, M. V., Sehgal, K., Nair, N., Mahajan, S., Sehrawat, T. S., Bikdeli, B., Ahluwalia, N., Ausiello, J. C., Wan, E. Y., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0968-3 · Cited by 3,185
Jothimani, D., Venugopal, R., Abedin, M. F., Kaliamoorthy, I., & Rela, M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.06.006 · Cited by 469
Pathophysiological mechanisms of liver injury in COVID‐19
Nardo, A. D., Schneeweiss‐Gleixner, M., Bakail, M., Dixon, E. D., Lax, S. F., & Trauner, M. (2021) · Liver International · doi:10.1111/liv.14730 · Cited by 397
Nanotechnology for COVID-19: Therapeutics and Vaccine Research
Chauhan, G., Madou, M. J., Kalra, S., Chopra, V., Ghosh, D., & Martinez-Chapa, S. O. (2020) · ACS Nano · doi:10.1021/acsnano.0c04006 · Cited by 385
COVID-19: Virology, biology and novel laboratory diagnosis
Mohamadian, M., Chiti, H., Shoghli, A., Biglari, S., Parsamanesh, N., & Esmaeilzadeh, A. (2021) · The Journal of Gene Medicine · doi:10.1002/jgm.3303 · Cited by 371
Metadata
- Authors
- Bangash, M. N., Patel, J., & Parekh, D.
- Venue
- The Lancet Gastroenterology & Hepatology
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 5
- Issue
- 6
- Pages
- 529-530
- ISSN
- 2468-1156 (ISSN-L)
- 2468-1253
- OpenAlex
- W3011408171
- Cited by
- 481
- References
- 15
- FWCI
- 13.49
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: COVID-19 and the liver: little cause for concern. https://app.cochat.ai/papers/10.1016/s2468-1253(20)30084-4
- The paper
- Bangash, M. N., Patel, J., & Parekh, D. (2020). COVID-19 and the liver: little cause for concern. The Lancet Gastroenterology & Hepatology. https://doi.org/10.1016/s2468-1253(20)30084-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.